Viewing Study NCT05137795

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 2:00 PM
Ignite Modification Date: 2026-02-10 @ 3:25 AM
Study NCT ID: NCT05137795
Status: WITHDRAWN
Last Update Posted: 2023-02-03
First Post: 2021-11-25
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19
Sponsor: APR Applied Pharma Research s.a.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None SARS-CoV 2 View
None COVID View
None ARDS View
None ALI View
None Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) View
None Dyspnea View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Corona Virus View
None VIP View
None Aviptadil View
None Vasoactive Intestinal Polypeptide View
None Zyesami View